Immunoassay Market by Product (Reagents & Kits, Analyzers), Technology (ELISA, CLIA, Western Blot), Specimen (Blood, Saliva, Urine), Application (Infectious Diseases, Endocrinology), End User (Hospitals & Clinics, Laboratories) - Global Forecast to 2030

1 INTRODUCTION 39 1.1 STUDY OBJECTIVES 39 1.2 MARKET DEFINITION 39 1.3 STUDY SCOPE 40 1.3.1 MARKET SEGMENTATION & REGIONAL SCOPE 40 1.3.2 INCLUSIONS & EXCLUSIONS 41 1.3.3 YEARS CONSIDERED 42 1.3.4 CURRENCY CONSIDERED 42 1.4 STAKEHOLDERS 42 1.5 SUMMARY OF CHANGES 43 2 RESEARCH METHODOLOGY 44 2.1 RESEARCH DATA 44 2.1.1 SECONDARY RESEARCH 45 2.1.1.1 Key secondary sources 45 2.1.1.2 Key data from secondary sources 46 2.1.2 PRIMARY RESEARCH 46 2.1.2.1 Key primary sources 47 2.1.2.2 Key objectives of primary research 47 2.1.2.3 Key data from primary sources 48 2.1.2.4 Key industry insights 49 2.2 MARKET SIZE ESTIMATION 51 2.2.1 BOTTOM-UP APPROACH 51 2.2.2 COMPANY PRESENTATIONS & PRIMARY INTERVIEWS 52 2.2.3 TOP-DOWN APPROACH 53 2.3 DATA TRIANGULATION 54 2.4 MARKET SHARE ANALYSIS 55 2.5 STUDY ASSUMPTIONS 55 2.5.1 MARKET ASSUMPTIONS 55 2.5.2 GROWTH RATE ASSUMPTIONS 55 2.6 RESEARCH LIMITATIONS 56 2.6.1 METHODOLOGY-RELATED LIMITATIONS 56 2.6.2 SCOPE-RELATED LIMITATIONS 56 2.7 RISK ANALYSIS 56 3 EXECUTIVE SUMMARY 57   4 PREMIUM INSIGHTS 63 4.1 IMMUNOASSAY MARKET OVERVIEW 63 4.2 NORTH AMERICA: IMMUNOASSAY MARKET, BY PRODUCT AND COUNTRY 64 4.3 IMMUNOASSAY MARKET: GEOGRAPHICAL SNAPSHOT 65 4.4 IMMUNOASSAY MARKET: REGIONAL MIX 66 5 MARKET OVERVIEW 67 5.1 INTRODUCTION 67 5.2 MARKET DYNAMICS 67 5.2.1 DRIVERS 68 5.2.1.1 Increasing incidence of chronic and infectious diseases 68 5.2.1.1.1 Increased use of immunoassays in oncology 69 5.2.1.1.2 Rising use of immunoassays in diagnostic applications 70 5.2.1.1.3 High geriatric population 71 5.2.1.2 Increased demand for blood donations in healthcare systems and surgical procedures 72 5.2.1.3 Growth in biotechnology & biopharmaceutical industries 72 5.2.1.4 Increasing adoption of immunoassay-based POC and rapid testing 73 5.2.1.5 Supportive government regulatory policies and initiatives 74 5.2.1.6 Increased consumption of drugs, alcohol, and cannabis 74 5.2.2 RESTRAINTS 75 5.2.2.1 Stringent requirements for approval of immunoassay instruments and consumables 75 5.2.2.2 Technical hurdles of immunoassay kits 75 5.2.3 OPPORTUNITIES 76 5.2.3.1 Increasing growth opportunities in emerging economies 76 5.2.3.2 Focus on importance of companion diagnostics 77 5.2.3.3 Development of condition-specific biomarkers and tests 78 5.2.3.4 Integration of microfluidics in immunoassays 79 5.2.3.5 Improving immunoassay diagnostic technologies 79 5.2.4 CHALLENGES 80 5.2.4.1 Design challenges and low quality of antibodies 80 5.2.4.2 Dearth of skilled professionals 80 5.3 REGULATORY ANALYSIS 80 5.3.1 REGULATORY FRAMEWORK 80 5.3.1.1 North America 80 5.3.1.1.1 US 80 5.3.1.1.2 Canada 82 5.3.1.2 Europe 82 5.3.1.2.1 Russia 83   5.3.1.3 Asia Pacific 83 5.3.1.3.1 Japan 83 5.3.1.3.2 China 85 5.3.1.3.3 India 85 5.3.1.3.4 Indonesia 86 5.3.1.3.5 South Korea 87 5.3.1.4 Middle East 87 5.3.1.4.1 Saudi Arabia 87 5.3.1.5 Latin America 88 5.3.1.5.1 Mexico 88 5.3.1.5.2 Brazil 89 5.3.1.6 Africa 90 5.3.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 90 5.4 TECHNOLOGY ANALYSIS 92 5.4.1 KEY TECHNOLOGIES 92 5.4.1.1 ELISA 92 5.4.2 ADJACENT TECHNOLOGIES 92 5.4.2.1 Microfluidics and miniaturized platforms 92 5.4.3 COMPLEMENTARY TECHNOLOGIES 92 5.4.3.1 Lateral flow assays 92 5.5 TRADE ANALYSIS 94 5.5.1 IMPORT DATA FOR HS CODE 382200, 2019–2024 94 5.5.2 EXPORT DATA FOR HS CODE 382200, 2019–2024 95 5.6 PATENT ANALYSIS 96 5.7 VALUE CHAIN ANALYSIS 97 5.8 SUPPLY CHAIN ANALYSIS 98 5.9 ECOSYSTEM ANALYSIS 99 5.9.1 ROLE IN ECOSYSTEM 100 5.10 PORTER’S FIVE FORCES ANALYSIS 101 5.10.1 INTENSITY OF COMPETITIVE RIVALRY 102 5.10.2 BARGAINING POWER OF SUPPLIERS 102 5.10.3 BARGAINING POWER OF BUYERS 102 5.10.4 THREAT OF SUBSTITUTES 102 5.10.5 THREAT OF NEW ENTRANTS 102 5.11 KEY STAKEHOLDERS & BUYING CRITERIA 103 5.11.1 KEY STAKEHOLDERS IN BUYING PROCESS 103 5.11.2 KEY BUYING CRITERIA 103 5.12 KEY CONFERENCES & EVENTS, 2025–2026 104   5.13 PRICING ANALYSIS 105 5.13.1 AVERAGE SELLING PRICE TREND OF IMMUNOASSAY PRODUCTS, BY KEY PLAYER, 2022–2024 105 5.13.2 AVERAGE SELLING PRICE TREND OF IMMUNOASSAY ANAYZERS, BY REGION, 2022–2024 106 5.13.3 AVERAGE SELLING PRICE TREND OF IMMUNOASSAY PRODUCTS, BY TYPE, 2022–2024 107 5.14 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 108 5.15 CASE STUDY ANALYSIS 109 5.15.1 PORTABLE MICROFLUIDIC CHEMILUMINESCENT IMMUNOASSAY TO BE USED FOR RAPID COVID 19 IMMUNITY MONITORING 109 5.15.2 MICROFLUIDIC-BASED IMMUNOASSAY TO HELP IN EARLY CANCER DETECTION 109 5.15.3 LUMINEX-BASED MULTIPLEX IMMUNOASSAY TO AID AUTOIMMUNE DISEASE PROFILING 110 5.16 INVESTMENT & FUNDING SCENARIO 110 5.17 IMPACT OF AI/GEN AI ON IMMUNOASSAY MARKET 111 5.17.1 MARKET POTENTIAL FOR IMMUNOASSAY PRODUCTS 111 5.17.2 FUTURE OF AI/GEN AI IN IMMUNOASSAY MARKET 112 5.18 IMPACT OF 2025 US TARIFF ON IMMUNOASSAY MARKET 113 5.18.1 INTRODUCTION 113 5.18.2 KEY TARIFF RATES 113 5.18.3 PRICE IMPACT ANALYSIS 114 5.18.4 IMPACT ON COUNTRY/REGION 115 5.18.4.1 North America 115 5.18.4.1.1 US 115 5.18.4.2 Europe 115 5.18.4.2.1 Germany 115 5.18.4.2.2 UK and France 115 5.18.4.3 Asia Pacific 116 5.18.4.3.1 China 116 5.18.4.3.2 Japan 116 5.18.4.3.3 India 116 5.18.5 IMPACT ON END-USE INDUSTRIES 116 5.18.5.1 Hospitals & clinics 116 5.18.5.2 Clinical laboratories 117 5.18.5.3 Blood banks 117 5.18.5.4 Home care settings 117   6 IMMUNOASSAY MARKET, BY PRODUCT 118 6.1 INTRODUCTION 119 6.2 REAGENTS & KITS 119 6.2.1 ELISA REAGENTS & KITS 124 6.2.1.1 Increased use of high-throughput screening in drug discovery programs to drive segment 124 6.2.2 RAPID TEST REAGENTS & KITS 127 6.2.2.1 High demand for preliminary screening tests in remote areas to propel segment growth 127 6.2.3 ELISPOT REAGENTS & KITS 130 6.2.3.1 High sensitivity, functionality, and adaptability of ELISpot technology to aid segment growth 130 6.2.4 CLIA REAGENTS & KITS 133 6.2.4.1 Better diagnosis and higher specificity to augment segment growth 133 6.2.5 IFA REAGENTS & KITS 136 6.2.5.1 Better adaptability in clinical diagnostics to support segment growth 136 6.2.6 WESTERN BLOT REAGENTS & KITS 139 6.2.6.1 Western blot reagents & kits to be considered gold standard for infectious disease test result validation 139 6.2.7 OTHER REAGENTS & KITS 142 6.3 ANALYZERS 144 6.3.1 IMMUNOASSAY ANALYZERS MARKET, BY TYPE 148 6.3.1.1 Open-ended systems 149 6.3.1.1.1 Better flexibility and wider availability to drive segment growth 149 6.3.1.2 Closed-ended systems 152 6.3.1.2.1 Higher precision and better automation to fuel segment growth 152 6.3.2 IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE 154 6.3.2.1 Rental purchase 155 6.3.2.1.1 Increased convenience and reduced liability to boost segment growth 155 6.3.2.2 Outright purchase 157 6.3.2.2.1 Inflated cost of immunoassay testing technologies to limit market growth 157 7 IMMUNOASSAY MARKET, BY TECHNOLOGY 160 7.1 INTRODUCTION 161 7.2 ELISA 164 7.2.1 BETTER SENSITIVITY AND QUICKER RESULTS TO DRIVE MARKET 164 7.3 CLIA 168 7.3.1 GOOD SPECIFICITY, WIDE LINEAR RANGE, AND HIGH SENSITIVITY TO AID MARKET GROWTH 168   7.4 IFA 171 7.4.1 IFA TO DIAGNOSE ANTIBODIES AND ANALYZE SMALL BIOLOGICAL AND NON-BIOLOGICAL MOLECULES 171 7.5 RAPID TESTS 174 7.5.1 FASTER RESULTS AND EASE OF USE TO DRIVE ADOPTION IN POINT-OF-CARE DIAGNOSIS AND EMERGENCY CARE SETTINGS 174 7.6 WESTERN BLOTTING 177 7.6.1 ABILITY TO DETECT AND CONFIRM ANTIBODIES OF RETROVIRUSES TO SPUR MARKET GROWTH 177 7.7 ELISPOT 180 7.7.1 HIGH SENSITIVITY, SPECIFICITY, AND VERSATILITY TO PROPEL MARKET GROWTH 180 7.8 OTHER TECHNOLOGIES 183 8 IMMUNOASSAY MARKET, BY SPECIMEN 187 8.1 INTRODUCTION 188 8.2 BLOOD 191 8.2.1 HIGH RELIABILITY AND INCREASED NEED DURING SURGICAL PROCEDURES TO AID MARKET GROWTH 191 8.3 SALIVA 194 8.3.1 ADVANCEMENTS IN IMMUNOASSAY-BASED SALIVA TESTS TO AUGMENT MARKET GROWTH 194 8.4 URINE 197 8.4.1 INCREASING USE BY LAW ENFORCEMENT AGENCIES AND RISING PREVALENCE OF KIDNEY DISEASES TO FAVOR MARKET GROWTH 197 8.5 OTHER SPECIMENS 200 9 IMMUNOASSAY MARKET, BY APPLICATION 204 9.1 INTRODUCTION 205 9.2 INFECTIOUS DISEASES 208 9.2.1 RISING PREVALENCE OF CHRONIC INFECTIOUS DISEASES TO DRIVE MARKET 208 9.3 ENDOCRINOLOGY 212 9.3.1 RISING INCIDENCE OF DIABETES TO AUGMENT MARKET GROWTH 212 9.4 CARDIOLOGY 215 9.4.1 HIGH BURDEN OF CARDIOVASCULAR DISEASES TO SUPPORT MARKET GROWTH 215 9.5 AUTOIMMUNE DISORDERS 219 9.5.1 HIGH INCIDENCE AND PREVALENCE OF AUTOIMMUNE DISEASES TO AUGMENT MARKET GROWTH 219 9.6 ALLERGY DIAGNOSTICS 222 9.6.1 GROWING PREVALENCE OF ALLERGIES TO AID MARKET GROWTH 222 9.7 ONCOLOGY 225 9.7.1 RISING BURDEN OF CANCER AND GROWING EMPHASIS ON EARLY DETECTION TO PROPEL MARKET GROWTH 225   9.8 BONE & MINERAL DISORDERS 228 9.8.1 INCREASING PREVALENCE OF OSTEOPOROSIS, VITAMIN D DEFICIENCY, AND ARTHRITIS TO AID MARKET GROWTH 228 9.9 DRUG MONITORING & TESTING 232 9.9.1 RISING DRUG ABUSE AND INCREASING ILLICIT DRUG CONSUMPTION TO ACCELERATE MARKET GROWTH 232 9.10 BLOOD SCREENING 236 9.10.1 RISING EMPHASIS ON BLOOD DONATIONS TO FAVOR MARKET GROWTH 236 9.11 NEWBORN SCREENING 239 9.11.1 TECHNOLOGICAL ADVANCEMENTS AND FAVORABLE GOVERNMENT INITIATIVES TO PROPEL MARKET GROWTH 239 9.12 OTHER APPLICATIONS 243 10 IMMUNOASSAY MARKET, BY END USER 246 10.1 INTRODUCTION 247 10.2 HOSPITALS & CLINICS 250 10.2.1 GROWING PATIENT POPULATION AND RISING TESTING VOLUME TO DRIVE MARKET 250 10.3 CLINICAL LABORATORIES 254 10.3.1 INCREASING NUMBER OF ACCREDITED LABORATORIES TO DRIVE MARKET 254 10.4 HOME CARE SETTINGS 257 10.4.1 RISING UTILIZATION OF POC DIAGNOSTICS AND AT-HOME ANTIGEN DIAGNOSIS TO PROPEL MARKET GROWTH 257 10.5 BLOOD BANKS 260 10.5.1 INCREASING NUMBER OF ACCIDENTS AND RISING DEMAND FOR BLOOD DURING SURGERIES TO SPUR MARKET GROWTH 260 11 IMMUNOASSAY MARKET, BY REGION 264 11.1 INTRODUCTION 265 11.2 NORTH AMERICA 265 11.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA 266 11.2.2 US 272 11.2.2.1 US to dominate North American immunoassay market during forecast period 272 11.2.3 CANADA 278 11.2.3.1 Increasing government support and rising incidence of chronic diseases to augment market growth 278 11.3 EUROPE 283 11.3.1 MACROECONOMIC OUTLOOK FOR EUROPE 283 11.3.2 GERMANY 289 11.3.2.1 High healthcare spending and favorable government initiatives to propel market growth 289 11.3.3 ITALY 294 11.3.3.1 Rising geriatric population and increasing cancer prevalence to spur market growth 294 11.3.4 FRANCE 298 11.3.4.1 Increased use of POC testing and favorable reimbursement policies to boost market growth 298 11.3.5 SPAIN 303 11.3.5.1 Increasing adoption of technologically advanced immunoassay systems to augment market growth 303 11.3.6 UK 307 11.3.6.1 Government support for disease diagnostics and favorable investment scenario to drive market 307 11.3.7 RUSSIA 313 11.3.7.1 Increasing access to quality healthcare and developing pharmaceutical industry to favor market growth 313 11.3.8 REST OF EUROPE 317 11.4 ASIA PACIFIC 322 11.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC 322 11.4.2 JAPAN 328 11.4.2.1 Increasing investments in healthcare technologies and research activities to fuel market growth 328 11.4.3 CHINA 333 11.4.3.1 Increasing government investments and rising geriatric population to accelerate maket growth 333 11.4.4 INDIA 337 11.4.4.1 Growing medical tourism and improving healthcare infrastructure to propel market growth 337 11.4.5 AUSTRALIA 342 11.4.5.1 Increasing incidence of cancer and rising focus on blood donations to favor market growth 342 11.4.6 SOUTH KOREA 347 11.4.6.1 Rising healthcare spending and increasing research investments to fuel market growth 347 11.4.7 INDONESIA 351 11.4.7.1 High geriatric population and favorable government healthcare policies to accelerate market growth 351 11.4.8 REST OF ASIA PACIFIC 356 11.5 LATIN AMERICA 360 11.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA 360 11.5.2 BRAZIL 365 11.5.2.1 High incidence of infectious diseases and presence of academic & research institutes to boost market growth 365 11.5.3 MEXICO 370 11.5.3.1 Increasing geriatric population and rising popularity of medical tourism to propel market growth 370 11.5.4 REST OF LATIN AMERICA 374 11.6 MIDDLE EAST & AFRICA 379 11.6.1 LACK OF SKILLED LABORATORY PERSONNEL AND UNFAVORABLE REIMBURSEMENT POLICIES TO LIMIT MARKET GROWTH 379 12 COMPETITIVE LANDSCAPE 384 12.1 INTRODUCTION 384 12.2 KEY PLAYER STRATEGIES/RIGHT TO WIN 384 12.2.1 OVERVIEW OF KEY STRATEGIES ADOPTED BY MAJOR PLAYERS IN IMMUNOASSAY MARKET 384 12.3 REVENUE ANALYSIS, 2020–2024 386 12.4 MARKET SHARE ANALYSIS, 2024 386 12.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024 388 12.5.1 STARS 388 12.5.2 EMERGING LEADERS 388 12.5.3 PERVASIVE PLAYERS 389 12.5.4 PARTICIPANTS 389 12.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2024 390 12.5.5.1 Company footprint 390 12.5.5.2 Region footprint 391 12.5.5.3 Product footprint 392 12.5.5.4 Specimen footprint 393 12.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024 394 12.6.1 PROGRESSIVE COMPANIES 394 12.6.2 RESPONSIVE COMPANIES 394 12.6.3 DYNAMIC COMPANIES 394 12.6.4 STARTING BLOCKS 394 12.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2024 396 12.6.5.1 List of key startups/SMEs 396 12.6.5.2 Competitive benchmarking of key startups/SMEs 397 12.7 COMPANY VALUATION & FINANCIAL METRICS 398 12.7.1 FINANCIAL METRICS 398 12.7.2 COMPANY VALUATION 398 12.8 BRAND/PRODUCT COMPARISON 399 12.9 COMPETITIVE SCENARIO 399 12.9.1 PRODUCT LAUNCHES/APPROVALS/ ENHANCEMENTS 399 12.9.2 DEALS 400 13 COMPANY PROFILES 402 13.1 KEY PLAYERS 402 13.1.1 ABBOTT 402 13.1.1.1 Business overview 402 13.1.1.2 Products offered 403 13.1.1.3 Recent developments 405 13.1.1.3.1 Product approvals 405 13.1.1.3.2 Deals 406 13.1.1.3.3 Expansions 407 13.1.1.4 MnM view 407 13.1.1.4.1 Right to win 407 13.1.1.4.2 Strategic choices 407 13.1.1.4.3 Weaknesses & competitive threats 407 13.1.2 F. HOFFMANN-LA ROCHE LTD. 408 13.1.2.1 Business overview 408 13.1.2.2 Products offered 409 13.1.2.3 Recent developments 412 13.1.2.3.1 Product launches and approvals 412 13.1.2.3.2 Deals 412 13.1.2.3.3 Expansions 413 13.1.2.4 MnM view 413 13.1.2.4.1 Right to win 413 13.1.2.4.2 Strategic choices 414 13.1.2.4.3 Weaknesses & competitive threats 414 13.1.3 SIEMENS HEALTHINEERS AG 415 13.1.3.1 Business overview 415 13.1.3.2 Products offered 416 13.1.3.3 Recent developments 418 13.1.3.3.1 Product launches and approvals 418 13.1.3.3.2 Deals 418 13.1.3.3.3 Expansions 419 13.1.3.4 MnM view 420 13.1.3.4.1 Right to win 420 13.1.3.4.2 Strategic choices 420 13.1.3.4.3 Weaknesses & competitive threats 420 13.1.4 DANAHER 421 13.1.4.1 Business overview 421 13.1.4.2 Products offered 422 13.1.4.3 Recent developments 423 13.1.4.3.1 Product launches and approvals 423 13.1.4.3.2 Deals 424 13.1.4.3.3 Expansions 425 13.1.4.4 MnM view 426 13.1.4.4.1 Right to win 426 13.1.4.4.2 Strategic choices 426 13.1.4.4.3 Weaknesses & competitive threats 426 13.1.5 THERMO FISHER SCIENTIFIC INC. 427 13.1.5.1 Business overview 427 13.1.5.2 Products offered 428 13.1.5.3 Recent developments 429 13.1.5.3.1 Product approvals 429 13.1.5.3.2 Deals 430 13.1.5.4 MnM view 430 13.1.5.4.1 Right to win 430 13.1.5.4.2 Strategic choices 431 13.1.5.4.3 Weaknesses & competitive threats 431 13.1.6 REVVITY 432 13.1.6.1 Business overview 432 13.1.6.2 Products offered 433 13.1.6.3 Recent developments 434 13.1.6.3.1 Product approvals 434 13.1.6.3.2 Other developments 435 13.1.7 BECTON, DICKINSON AND COMPANY (BD) 436 13.1.7.1 Business overview 436 13.1.7.2 Products offered 437 13.1.7.3 Recent developments 438 13.1.7.3.1 Expansions 438 13.1.8 DIASORIN S.P.A. 439 13.1.8.1 Business overview 439 13.1.8.2 Products offered 440 13.1.8.3 Recent developments 442 13.1.8.3.1 Product launches and approvals 442 13.1.8.3.2 Deals 443 13.1.9 BIO-RAD LABORATORIES, INC. 444 13.1.9.1 Business overview 444 13.1.9.2 Products offered 445 13.1.9.3 Recent developments 447 13.1.9.3.1 Product launches 447 13.1.9.3.2 Deals 448 13.1.10 QUIDELORTHO CORPORATION 449 13.1.10.1 Business overview 449 13.1.10.2 Products offered 450 13.1.10.3 Recent developments 453 13.1.10.3.1 Product approvals 453 13.1.10.3.2 Deals 453 13.1.10.3.3 Expansions 454 13.1.11 BIOMÉRIEUX 455 13.1.11.1 Business overview 455 13.1.11.2 Products offered 456 13.1.11.3 Recent developments 457 13.1.11.3.1 Product launches and approvals 457 13.1.11.3.2 Deals 458   13.1.12 QIAGEN 459 13.1.12.1 Business overview 459 13.1.12.2 Products offered 460 13.1.12.3 Recent developments 461 13.1.12.3.1 Deals 461 13.1.13 SYSMEX CORPORATION 462 13.1.13.1 Business overview 462 13.1.13.2 Products offered 464 13.1.13.3 Recent developments 464 13.1.13.3.1 Deals 464 13.1.13.3.2 Expansions 465 13.1.14 AGILENT TECHNOLOGIES, INC. 467 13.1.14.1 Business overview 467 13.1.14.2 Products offered 468 13.1.14.3 Recent developments 469 13.1.14.3.1 Product launches and approvals 469 13.1.14.3.2 Deals 469 13.1.14.3.3 Other developments 470 13.1.15 SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD. 471 13.1.15.1 Business overview 471 13.1.15.2 Products offered 472 13.2 OTHER PLAYERS 473 13.2.1 MERCK KGAA 473 13.2.2 MERIDIAN BIOSCIENCE 474 13.2.3 BIO-TECHNE 475 13.2.4 CELLABS 476 13.2.5 ABNOVA CORPORATION 477 13.2.6 J. MITRA & CO. PVT. LTD. 477 13.2.7 TOSOH CORPORATION (TOSOH BIOSCIENCES) 478 13.2.8 CELL SCIENCES 478 13.2.9 ENZO BIOCHEM INC. 479 13.2.10 CREATIVE DIAGNOSTICS 480 13.2.11 BOSTER BIOLOGICAL TECHNOLOGY 480 13.2.12 ELABSCIENCE BIONOVATON INC. 481 13.2.13 WAK-CHEMIE MEDICAL GMBH 481 13.2.14 SERA CARE 482 13.2.15 EPITOPE DIAGNOSTICS, INC. 482 13.2.16 KAMIYA BIOMEDICAL COMPANY 483 13.2.17 GYROS PROTEIN TECHNOLOGIES AB 483 13.2.18 TRIVITRON HEALTHCARE 484 13.2.19 INBIOS INTERNATIONAL, INC. 484 13.2.20 MACCURA BIOTECHNOLOGY CO., LTD. 485 14 APPENDIX 486 14.1 DISCUSSION GUIDE 486 14.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 490 14.3 CUSTOMIZATION OPTIONS 492 14.4 RELATED REPORTS 492

TABLE 1 IMMUNOASSAY MARKET: INCLUSIONS & EXCLUSIONS 41 TABLE 2 IMMUNOASSAY MARKET: KEY DATA FROM PRIMARY SOURCES 48 TABLE 3 IMMUNOASSAY MARKET: MARKET ASSUMPTIONS 55 TABLE 4 IMMUNOASSAY MARKET: RISK ANALYSIS 56 TABLE 5 INCREASING INCIDENCE OF CANCER, BY REGION, 2020 VS. 2030 VS. 2040 (MILLION) 69 TABLE 6 PROJECTED NUMBER OF CANCER PATIENTS, BY CANCER TYPE, 2015 VS. 2018 VS. 2035 (UNITS) 70 TABLE 7 DETECTION TIME OF DRUG OR DRUG CLASS IN URINE TESTING 70 TABLE 8 ESTIMATED PERCENTAGE INCREASE IN GERIATRIC POPULATION, BY REGION, 2022 VS. 2030 VS. 2050 71 TABLE 9 RECENT DEVELOPMENTS IN IMMUNOASSAY MARKET, 2021–2023 77 TABLE 10 NEW TESTS LAUNCHED BY KEY PLAYERS, 2021–2023 78 TABLE 11 LAB-ON-CHIP IMMUNOASSAYS/DEVICES/SYSTEMS OFFERED BY KEY PLAYERS 79 TABLE 12 US: CLASSIFICATION AND RISK LEVEL OF IMMUNOASSAY PRODUCTS 81 TABLE 13 EUROPE: CLASSIFICATION AND RISK LEVEL OF IN-VIRTO DIAGNOSTIC DEVICES 82 TABLE 14 RUSSIA: CLASSIFICATION AND RISK LEVEL OF IN-VIRTO DIAGNOSTIC DEVICES 83 TABLE 15 JAPAN: CLASSIFICATION OF IN-VIRTO DIAGNOSTIC REAGENTS 84 TABLE 16 JAPAN: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS 85 TABLE 17 CHINA: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS 85 TABLE 18 INDONESIA: REGISTRATION PROCESS FOR IN-VIRTO DIAGNOSTIC DEVICES 86 TABLE 19 SOUTH KOREA: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS 87 TABLE 20 SAUDI ARABIA: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS 88 TABLE 21 MEXICO: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS 89 TABLE 22 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 90 TABLE 23 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 91 TABLE 24 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 91 TABLE 25 LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 91 TABLE 26 REST OF THE WORLD: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 92 TABLE 27 CONVENTIONAL IMMUNOASSAY METHODS AND TECHNIQUES 93 TABLE 28 RECENT PRODUCT LAUNCHES WITH ADVANCED TECHNOLOGIES IN IMMUNOASSAY MARKET 94 TABLE 29 IMPORT DATA FOR HS CODE 382200, BY COUNTRY, 2019–2024 (USD MILLION) 95 TABLE 30 EXPORT DATA FOR HS CODE 382200, BY COUNTRY, 2019–2024 (USD MILLION) 95 TABLE 31 IMMUNOASSAY MARKET: ROLE IN ECOSYSTEM 100 TABLE 32 IMMUNOASSAY MARKET: PORTER’S FIVE FORCES 101 TABLE 33 INFLUENCE OF KEY STAKEHOLDERS ON BUYING PROCESS 103 TABLE 34 KEY BUYING CRITERIA, BY END USER 104 TABLE 35 IMMUNOASSAY MARKET: LIST OF KEY CONFERENCES & EVENTS, JANUARY 2025–DECEMBER 2026 104 TABLE 36 AVERAGE SELLING PRICE TREND OF IMMUNOASSAY PRODUCTS, BY KEY PLAYER, 2022–2024 (USD) 105 TABLE 37 AVERAGE SELLING PRICE TREND OF CLINICAL IMMUNOASSAY ANALYZERS, BY REGION, 2022–2024 (USD) 106 TABLE 38 AVERAGE SELLING PRICE TREND OF IMMUNOASSAY PRODUCTS, BY TYPE, 2022–2024 (USD) 107 TABLE 39 CASE STUDY 1: PORTABLE MICROFLUIDIC CHEMILUMINESCENT IMMUNOASSAY TO BE USED FOR RAPID COVID 19 IMMUNITY MONITORING 109 TABLE 40 CASE STUDY 2: MICROFLUIDIC-BASED IMMUNOASSAY TO HELP IN EARLY CANCER DETECTION 109 TABLE 41 CASE STUDY 3: LUMINEX-BASED MULTIPLEX IMMUNOASSAY TO AID AUTOIMMUNE DISEASE PROFILING 110 TABLE 42 US ADJUSTED RECIPROCAL TARIFF RATES 113 TABLE 43 IMMUNOASSAY MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 119 TABLE 44 KEY REAGENTS & KITS AVAILABLE IN MARKET 120 TABLE 45 IMMUNOASSAY REAGENTS & KITS MARKET, BY REGION, 2023–2030 (USD MILLION) 121 TABLE 46 IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE, 2023–2030 (USD MILLION) 121 TABLE 47 NORTH AMERICA: IMMUNOASSAY REAGENTS & KITS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 122 TABLE 48 EUROPE: IMMUNOASSAY REAGENTS & KITS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 122 TABLE 49 ASIA PACIFIC: IMMUNOASSAY REAGENTS & KITS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 123 TABLE 50 LATIN AMERICA: IMMUNOASSAY REAGENTS & KITS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 123 TABLE 51 ELISA REAGENTS & KITS MARKET, BY REGION, 2023–2030 (USD MILLION) 125 TABLE 52 NORTH AMERICA: ELISA REAGENTS & KITS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 125 TABLE 53 EUROPE: ELISA REAGENTS & KITS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 126 TABLE 54 ASIA PACIFIC: ELISA REAGENTS & KITS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 126 TABLE 55 LATIN AMERICA: ELISA REAGENTS & KITS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 127 TABLE 56 RAPID TEST REAGENTS & KITS MARKET, BY REGION, 2023–2030 (USD MILLION) 128 TABLE 57 NORTH AMERICA: RAPID TEST REAGENTS & KITS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 128 TABLE 58 EUROPE: RAPID TEST REAGENTS & KITS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 129 TABLE 59 ASIA PACIFIC: RAPID TEST REAGENTS & KITS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 129 TABLE 60 LATIN AMERICA: RAPID TEST REAGENTS & KITS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 130 TABLE 61 ELISPOT REAGENTS & KITS MARKET, BY REGION, 2023–2030 (USD MILLION) 131 TABLE 62 NORTH AMERICA: ELISPOT REAGENTS & KITS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 131 TABLE 63 EUROPE: ELISPOT REAGENTS & KITS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 132 TABLE 64 ASIA PACIFIC: ELISPOT REAGENTS & KITS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 132 TABLE 65 LATIN AMERICA: ELISPOT REAGENTS & KITS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 133 TABLE 66 CLIA REAGENTS & KITS MARKET, BY REGION, 2023–2030 (USD MILLION) 134 TABLE 67 NORTH AMERICA: CLIA REAGENTS & KITS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 134 TABLE 68 EUROPE: CLIA REAGENTS & KITS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 135 TABLE 69 ASIA PACIFIC: CLIA REAGENTS & KITS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 135 TABLE 70 LATIN AMERICA: CLIA REAGENTS & KITS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 136 TABLE 71 IFA REAGENTS & KITS MARKET, BY REGION, 2023–2030 (USD MILLION) 136 TABLE 72 NORTH AMERICA: IFA REAGENTS & KITS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 137 TABLE 73 EUROPE: IFA REAGENTS & KITS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 137 TABLE 74 ASIA PACIFIC: IFA REAGENTS & KITS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 138 TABLE 75 LATIN AMERICA: IFA REAGENTS & KITS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 138 TABLE 76 WESTERN BLOT REAGENTS & KITS MARKET, BY REGION, 2023–2030 (USD MILLION) 139 TABLE 77 NORTH AMERICA: WESTERN BLOT REAGENTS & KITS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 140 TABLE 78 EUROPE: WESTERN BLOT REAGENTS & KITS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 140 TABLE 79 ASIA PACIFIC: WESTERN BLOT REAGENTS & KITS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 141 TABLE 80 LATIN AMERICA: WESTERN BLOT REAGENTS & KITS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 141 TABLE 81 OTHER REAGENTS & KITS MARKET, BY REGION, 2023–2030 (USD MILLION) 142 TABLE 82 NORTH AMERICA: OTHER REAGENTS & KITS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 142 TABLE 83 EUROPE: OTHER REAGENTS & KITS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 143 TABLE 84 ASIA PACIFIC: OTHER REAGENTS & KITS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 143 TABLE 85 LATIN AMERICA: OTHER REAGENTS & KITS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 144 TABLE 86 KEY ANALYZERS AVAILABLE IN MARKET 145 TABLE 87 IMMUNOASSAY ANALYZERS MARKET, BY REGION, 2023–2030 (USD MILLION) 146 TABLE 88 NORTH AMERICA: IMMUNOASSAY ANALYZERS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 146 TABLE 89 EUROPE: IMMUNOASSAY ANALYZERS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 147 TABLE 90 ASIA PACIFIC: IMMUNOASSAY ANALYZERS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 147 TABLE 91 LATIN AMERICA: IMMUNOASSAY ANALYZERS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 148 TABLE 92 IMMUNOASSAY ANALYZERS MARKET, BY TYPE, 2023–2030 (USD MILLION) 149 TABLE 93 OPEN-ENDED SYSTEMS MARKET, BY REGION, 2023–2030 (USD MILLION) 149 TABLE 94 NORTH AMERICA: OPEN-ENDED SYSTEMS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 150 TABLE 95 EUROPE: OPEN-ENDED SYSTEMS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 150 TABLE 96 ASIA PACIFIC: OPEN-ENDED SYSTEMS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 151 TABLE 97 LATIN AMERICA: OPEN-ENDED SYSTEMS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 151 TABLE 98 CLOSED-ENDED SYSTEMS MARKET, BY REGION, 2023–2030 (USD MILLION) 152 TABLE 99 NORTH AMERICA: CLOSED-ENDED SYSTEMS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 152 TABLE 100 EUROPE: CLOSED-ENDED SYSTEMS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 153 TABLE 101 ASIA PACIFIC: CLOSED-ENDED SYSTEMS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 153 TABLE 102 LATIN AMERICA: CLOSED-ENDED SYSTEMS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 154 TABLE 103 IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE, 2023–2030 (USD MILLION) 154 TABLE 104 RENTAL PURCHASE MARKET, BY REGION, 2023–2030 (USD MILLION) 155 TABLE 105 NORTH AMERICA: RENTAL PURCHASE MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 155 TABLE 106 EUROPE: RENTAL PURCHASE MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 156 TABLE 107 ASIA PACIFIC: RENTAL PURCHASE MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 156 TABLE 108 LATIN AMERICA: RENTAL PURCHASE MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 157 TABLE 109 OUTRIGHT PURCHASE MARKET, BY REGION, 2023–2030 (USD MILLION) 157 TABLE 110 NORTH AMERICA: OUTRIGHT PURCHASE MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 158 TABLE 111 EUROPE: OUTRIGHT PURCHASE MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 158 TABLE 112 ASIA PACIFIC: OUTRIGHT PURCHASE MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 159 TABLE 113 LATIN AMERICA: OUTRIGHT PURCHASE MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 159 TABLE 114 IMMUNOASSAY MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 161 TABLE 115 IMMUNOASSAY TECHNOLOGY MARKET, BY REGION, 2023–2030 (USD MILLION) 161 TABLE 116 NORTH AMERICA: IMMUNOASSAY TECHNOLOGY MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 162 TABLE 117 EUROPE: IMMUNOASSAY TECHNOLOGY MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 162 TABLE 118 ASIA PACIFIC: IMMUNOASSAY TECHNOLOGY MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 163 TABLE 119 LATIN AMERICA: IMMUNOASSAY TECHNOLOGY MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 163 TABLE 120 KEY ELISA TECHNOLOGIES AVAILABLE IN MARKET 164 TABLE 121 IMMUNOASSAY MARKET FOR ELISA, BY REGION, 2023–2030 (USD MILLION) 165 TABLE 122 NORTH AMERICA: IMMUNOASSAY MARKET FOR ELISA, BY COUNTRY, 2023–2030 (USD MILLION) 166 TABLE 123 EUROPE: IMMUNOASSAY MARKET FOR ELISA, BY COUNTRY, 2023–2030 (USD MILLION) 166 TABLE 124 ASIA PACIFIC: IMMUNOASSAY MARKET ELISA, BY COUNTRY, 2023–2030 (USD MILLION) 167 TABLE 125 LATIN AMERICA: IMMUNOASSAY MARKET FOR ELISA, BY COUNTRY, 2023–2030 (USD MILLION) 167 TABLE 126 IMMUNOASSAY MARKET FOR CLIA, BY REGION, 2023–2030 (USD MILLION) 169 TABLE 127 NORTH AMERICA: IMMUNOASSAY MARKET FOR CLIA, BY COUNTRY, 2023–2030 (USD MILLION) 169 TABLE 128 EUROPE: IMMUNOASSAY MARKET FOR CLIA, BY COUNTRY, 2023–2030 (USD MILLION) 170 TABLE 129 ASIA PACIFIC: IMMUNOASSAY MARKET CLIA, BY COUNTRY, 2023–2030 (USD MILLION) 170 TABLE 130 LATIN AMERICA: IMMUNOASSAY MARKET FOR CLIA, BY COUNTRY, 2023–2030 (USD MILLION) 171 TABLE 131 IMMUNOASSAY MARKET FOR IFA, BY REGION, 2023–2030 (USD MILLION) 172 TABLE 132 NORTH AMERICA: IMMUNOASSAY MARKET FOR IFA, BY COUNTRY, 2023–2030 (USD MILLION) 172 TABLE 133 EUROPE: IMMUNOASSAY MARKET FOR IFA, BY COUNTRY, 2023–2030 (USD MILLION) 173 TABLE 134 ASIA PACIFIC: IMMUNOASSAY MARKET IFA, BY COUNTRY, 2023–2030 (USD MILLION) 173 TABLE 135 LATIN AMERICA: IMMUNOASSAY MARKET FOR IFA, BY COUNTRY, 2023–2030 (USD MILLION) 174 TABLE 136 KEY RAPID TESTS AVAILABLE IN MARKET 174 TABLE 137 IMMUNOASSAY MARKET FOR RAPID TESTS, BY REGION, 2023–2030 (USD MILLION) 175 TABLE 138 NORTH AMERICA: IMMUNOASSAY MARKET FOR RAPID TESTS, BY COUNTRY, 2023–2030 (USD MILLION) 175 TABLE 139 EUROPE: IMMUNOASSAY MARKET FOR RAPID TESTS, BY COUNTRY, 2023–2030 (USD MILLION) 176 TABLE 140 ASIA PACIFIC: IMMUNOASSAY MARKET RAPID TESTS, BY COUNTRY, 2023–2030 (USD MILLION) 176 TABLE 141 LATIN AMERICA: IMMUNOASSAY MARKET FOR RAPID TESTS, BY COUNTRY, 2023–2030 (USD MILLION) 177 TABLE 142 KEY WESTERN BLOTTING SYSTEMS AVAILABLE IN MARKET 177 TABLE 143 IMMUNOASSAY MARKET FOR WESTERN BLOTTING, BY REGION, 2023–2030 (USD MILLION) 178 TABLE 144 NORTH AMERICA: IMMUNOASSAY MARKET FOR WESTERN BLOTTING, BY COUNTRY, 2023–2030 (USD MILLION) 178 TABLE 145 EUROPE: IMMUNOASSAY MARKET FOR WESTERN BLOTTING, BY COUNTRY, 2023–2030 (USD MILLION) 179 TABLE 146 ASIA PACIFIC: IMMUNOASSAY MARKET WESTERN BLOTTING, BY COUNTRY, 2023–2030 (USD MILLION) 179 TABLE 147 LATIN AMERICA: IMMUNOASSAY MARKET FOR WESTERN BLOTTING, BY COUNTRY, 2023–2030 (USD MILLION) 180 TABLE 148 IMMUNOASSAY MARKET FOR ELISPOT, BY REGION, 2023–2030 (USD MILLION) 181 TABLE 149 NORTH AMERICA: IMMUNOASSAY MARKET FOR ELISPOT, BY COUNTRY, 2023–2030 (USD MILLION) 181 TABLE 150 EUROPE: IMMUNOASSAY MARKET FOR ELISPOT, BY COUNTRY, 2023–2030 (USD MILLION) 182 TABLE 151 ASIA PACIFIC: IMMUNOASSAY MARKET FOR ELISPOT, BY COUNTRY, 2023–2030 (USD MILLION) 182 TABLE 152 LATIN AMERICA: IMMUNOASSAY MARKET FOR ELISPOT, BY COUNTRY, 2023–2030 (USD MILLION) 183 TABLE 153 IMMUNOASSAY MARKET FOR OTHER TECHNOLOGIES, BY REGION, 2023–2030 (USD MILLION) 184 TABLE 154 NORTH AMERICA: IMMUNOASSAY MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2023–2030 (USD MILLION) 184 TABLE 155 EUROPE: IMMUNOASSAY MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2023–2030 (USD MILLION) 185 TABLE 156 ASIA PACIFIC: IMMUNOASSAY MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2023–2030 (USD MILLION) 185 TABLE 157 LATIN AMERICA: IMMUNOASSAY MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2023–2030 (USD MILLION) 186 TABLE 158 IMMUNOASSAY MARKET, BY SPECIMEN, 2023–2030 (USD MILLION) 188 TABLE 159 IMMUNOASSAY SPECIMEN MARKET, BY REGION, 2023–2030 (USD MILLION) 188 TABLE 160 NORTH AMERICA: IMMUNOASSAY SPECIMEN MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 189 TABLE 161 EUROPE: IMMUNOASSAY SPECIMEN MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 189 TABLE 162 ASIA PACIFIC: IMMUNOASSAY SPECIMEN MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 190 TABLE 163 LATIN AMERICA: IMMUNOASSAY SPECIMEN MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 190 TABLE 164 IMMUNOASSAY MARKET FOR BLOOD, BY REGION, 2023–2030 (USD MILLION) 192 TABLE 165 NORTH AMERICA: IMMUNOASSAY MARKET FOR BLOOD, BY COUNTRY, 2023–2030 (USD MILLION) 192 TABLE 166 EUROPE: IMMUNOASSAY MARKET FOR BLOOD, BY COUNTRY, 2023–2030 (USD MILLION) 193 TABLE 167 ASIA PACIFIC: IMMUNOASSAY MARKET FOR BLOOD, BY COUNTRY, 2023–2030 (USD MILLION) 193 TABLE 168 LATIN AMERICA: IMMUNOASSAY MARKET FOR BLOOD, BY COUNTRY, 2023–2030 (USD MILLION) 194 TABLE 169 IMMUNOASSAY MARKET FOR SALIVA, BY REGION, 2023–2030 (USD MILLION) 195 TABLE 170 NORTH AMERICA: IMMUNOASSAY MARKET FOR SALIVA, BY COUNTRY, 2023–2030 (USD MILLION) 195 TABLE 171 EUROPE: IMMUNOASSAY MARKET FOR SALIVA, BY COUNTRY, 2023–2030 (USD MILLION) 196 TABLE 172 ASIA PACIFIC: IMMUNOASSAY MARKET FOR SALIVA, BY COUNTRY, 2023–2030 (USD MILLION) 196 TABLE 173 LATIN AMERICA: IMMUNOASSAY MARKET FOR SALIVA, BY COUNTRY, 2023–2030 (USD MILLION) 197 TABLE 174 IMMUNOASSAY MARKET FOR URINE, BY REGION, 2023–2030 (USD MILLION) 198 TABLE 175 NORTH AMERICA: IMMUNOASSAY MARKET FOR URINE, BY COUNTRY, 2023–2030 (USD MILLION) 198 TABLE 176 EUROPE: IMMUNOASSAY MARKET FOR URINE, BY COUNTRY, 2023–2030 (USD MILLION) 199 TABLE 177 ASIA PACIFIC: IMMUNOASSAY MARKET FOR URINE, BY COUNTRY, 2023–2030 (USD MILLION) 199 TABLE 178 LATIN AMERICA: IMMUNOASSAY MARKET FOR URINE, BY COUNTRY, 2023–2030 (USD MILLION) 200 TABLE 179 IMMUNOASSAY MARKET FOR OTHER SPECIMENS, BY REGION, 2023–2030 (USD MILLION) 201 TABLE 180 NORTH AMERICA: IMMUNOASSAY MARKET FOR OTHER SPECIMENS, BY COUNTRY, 2023–2030 (USD MILLION) 201 TABLE 181 EUROPE: IMMUNOASSAY MARKET FOR OTHER SPECIMENS, BY COUNTRY, 2023–2030 (USD MILLION) 202 TABLE 182 ASIA PACIFIC: IMMUNOASSAY MARKET FOR OTHER SPECIMENS, BY COUNTRY, 2023–2030 (USD MILLION) 202 TABLE 183 LATIN AMERICA: IMMUNOASSAY MARKET FOR OTHER SPECIMENS, BY COUNTRY, 2023–2030 (USD MILLION) 203 TABLE 184 IMMUNOASSAY MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 205 TABLE 185 IMMUNOASSAY APPLICATION MARKET, BY REGION, 2023–2030 (USD MILLION) 206 TABLE 186 NORTH AMERICA: IMMUNOASSAY APPLICATION MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 206 TABLE 187 EUROPE: IMMUNOASSAY APPLICATION MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 207 TABLE 188 ASIA PACIFIC: IMMUNOASSAY APPLICATION MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 207 TABLE 189 LATIN AMERICA: IMMUNOASSAY APPLICATION MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 208 TABLE 190 IMMUNOASSAY MARKET FOR INFECTIOUS DISEASES, BY REGION, 2023–2030 (USD MILLION) 209 TABLE 191 NORTH AMERICA: IMMUNOASSAY MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2023–2030 (USD MILLION) 210 TABLE 192 EUROPE: IMMUNOASSAY MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2023–2030 (USD MILLION) 210 TABLE 193 ASIA PACIFIC: IMMUNOASSAY MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2023–2030 (USD MILLION) 211 TABLE 194 LATIN AMERICA: IMMUNOASSAY MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2023–2030 (USD MILLION) 211 TABLE 195 IMMUNOASSAY MARKET FOR ENDOCRINOLOGY, BY REGION, 2023–2030 (USD MILLION) 212 TABLE 196 NORTH AMERICA: IMMUNOASSAY MARKET FOR ENDOCRINOLOGY, BY COUNTRY, 2023–2030 (USD MILLION) 213 TABLE 197 EUROPE: IMMUNOASSAY MARKET FOR ENDOCRINOLOGY, BY COUNTRY, 2023–2030 (USD MILLION) 213 TABLE 198 ASIA PACIFIC: IMMUNOASSAY MARKET FOR ENDOCRINOLOGY, BY COUNTRY, 2023–2030 (USD MILLION) 214 TABLE 199 LATIN AMERICA: IMMUNOASSAY MARKET FOR ENDOCRINOLOGY, BY COUNTRY, 2023–2030 (USD MILLION) 214 TABLE 200 KEY PRODUCTS AVAILABLE FOR CARDIOLOGY APPLICATIONS 216 TABLE 201 IMMUNOASSAY MARKET FOR CARDIOLOGY, BY REGION, 2023–2030 (USD MILLION) 216 TABLE 202 NORTH AMERICA: IMMUNOASSAY MARKET FOR CARDIOLOGY, BY COUNTRY, 2023–2030 (USD MILLION) 217 TABLE 203 EUROPE: IMMUNOASSAY MARKET FOR CARDIOLOGY, BY COUNTRY, 2023–2030 (USD MILLION) 217 TABLE 204 ASIA PACIFIC: IMMUNOASSAY MARKET FOR CARDIOLOGY, BY COUNTRY, 2023–2030 (USD MILLION) 218 TABLE 205 LATIN AMERICA: IMMUNOASSAY MARKET FOR CARDIOLOGY, BY COUNTRY, 2023–2030 (USD MILLION) 218 TABLE 206 IMMUNOASSAY MARKET FOR AUTOIMMUNE DISORDERS, BY REGION, 2023–2030 (USD MILLION) 219 TABLE 207 NORTH AMERICA: IMMUNOASSAY MARKET FOR AUTOIMMUNE DISORDERS, BY COUNTRY, 2023–2030 (USD MILLION) 220 TABLE 208 EUROPE: IMMUNOASSAY MARKET FOR AUTOIMMUNE DISORDERS, BY COUNTRY, 2023–2030 (USD MILLION) 220 TABLE 209 ASIA PACIFIC: IMMUNOASSAY MARKET FOR AUTOIMMUNE DISORDERS, BY COUNTRY, 2023–2030 (USD MILLION) 221 TABLE 210 LATIN AMERICA: IMMUNOASSAY MARKET FOR AUTOIMMUNE DISORDERS, BY COUNTRY, 2023–2030 (USD MILLION) 221 TABLE 211 IMMUNOASSAY MARKET FOR ALLERGY DIAGNOSTICS, BY REGION, 2023–2030 (USD MILLION) 222 TABLE 212 NORTH AMERICA: IMMUNOASSAY MARKET FOR ALLERGY DIAGNOSTICS, BY COUNTRY, 2023–2030 (USD MILLION) 223 TABLE 213 EUROPE: IMMUNOASSAY MARKET FOR ALLERGY DIAGNOSTICS, BY COUNTRY, 2023–2030 (USD MILLION) 223 TABLE 214 ASIA PACIFIC: IMMUNOASSAY MARKET FOR ALLERGY DIAGNOSTICS, BY COUNTRY, 2023–2030 (USD MILLION) 224 TABLE 215 LATIN AMERICA: IMMUNOASSAY MARKET FOR ALLERGY DIAGNOSTICS, BY COUNTRY, 2023–2030 (USD MILLION) 224 TABLE 216 INCREASING INCIDENCE OF CANCER, BY REGION, 2021 VS. 2030 VS. 2040 (MILLION) 225 TABLE 217 IMMUNOASSAY MARKET FOR ONCOLOGY, BY REGION, 2023–2030 (USD MILLION) 226 TABLE 218 NORTH AMERICA: IMMUNOASSAY MARKET FOR ONCOLOGY, BY COUNTRY, 2023–2030 (USD MILLION) 226 TABLE 219 EUROPE: IMMUNOASSAY MARKET FOR ONCOLOGY, BY COUNTRY, 2023–2030 (USD MILLION) 227 TABLE 220 ASIA PACIFIC: IMMUNOASSAY MARKET FOR ONCOLOGY, BY COUNTRY, 2023–2030 (USD MILLION) 227 TABLE 221 LATIN AMERICA: IMMUNOASSAY MARKET FOR ONCOLOGY, BY COUNTRY, 2023–2030 (USD MILLION) 228 TABLE 222 KEY PRODUCTS AVAILABLE FOR BONE & MINERAL DISORDERS 229 TABLE 223 IMMUNOASSAY MARKET FOR BONE & MINERAL DISORDERS, BY REGION, 2023–2030 (USD MILLION) 230 TABLE 224 NORTH AMERICA: IMMUNOASSAY MARKET FOR BONE & MINERAL DISORDERS, BY COUNTRY, 2023–2030 (USD MILLION) 230 TABLE 225 EUROPE: IMMUNOASSAY MARKET FOR BONE & MINERAL DISORDERS, BY COUNTRY, 2023–2030 (USD MILLION) 231 TABLE 226 ASIA PACIFIC: IMMUNOASSAY MARKET FOR BONE & MINERAL DISORDERS, BY COUNTRY, 2023–2030 (USD MILLION) 231 TABLE 227 LATIN AMERICA: IMMUNOASSAY MARKET FOR BONE & MINERAL DISORDERS, BY COUNTRY, 2023–2030 (USD MILLION) 232 TABLE 228 KEY PRODUCTS AVAILABLE FOR DRUG MONITORING & TESTING 233 TABLE 229 KEY IMMUNOASSAY PRODUCTS AVAILABLE FOR DRUG MONITORING & TESTING 233 TABLE 230 IMMUNOASSAY MARKET FOR DRUG MONITORING & TESTING, BY REGION, 2023–2030 (USD MILLION) 234 TABLE 231 NORTH AMERICA: IMMUNOASSAY MARKET FOR DRUG MONITORING & TESTING, BY COUNTRY, 2023–2030 (USD MILLION) 234 TABLE 232 EUROPE: IMMUNOASSAY MARKET FOR DRUG MONITORING & TESTING, BY COUNTRY, 2023–2030 (USD MILLION) 235 TABLE 233 ASIA PACIFIC: IMMUNOASSAY MARKET FOR DRUG MONITORING & TESTING, BY COUNTRY, 2023–2030 (USD MILLION) 235 TABLE 234 LATIN AMERICA: IMMUNOASSAY MARKET FOR DRUG MONITORING & TESTING, BY COUNTRY, 2023–2030 (USD MILLION) 236 TABLE 235 IMMUNOASSAY MARKET FOR BLOOD SCREENING, BY REGION, 2023–2030 (USD MILLION) 237 TABLE 236 NORTH AMERICA: IMMUNOASSAY MARKET FOR BLOOD SCREENING, BY COUNTRY, 2023–2030 (USD MILLION) 237 TABLE 237 EUROPE: IMMUNOASSAY MARKET FOR BLOOD SCREENING, BY COUNTRY, 2023–2030 (USD MILLION) 238 TABLE 238 ASIA PACIFIC: IMMUNOASSAY MARKET FOR BLOOD SCREENING, BY COUNTRY, 2023–2030 (USD MILLION) 238 TABLE 239 LATIN AMERICA: IMMUNOASSAY MARKET FOR BLOOD SCREENING, BY COUNTRY, 2023–2030 (USD MILLION) 239 TABLE 240 KEY PRODUCTS AVAILABLE FOR NEWBORN SCREENING 239 TABLE 241 IMMUNOASSAY MARKET FOR NEWBORN SCREENING, BY REGION, 2023–2030 (USD MILLION) 240 TABLE 242 NORTH AMERICA: IMMUNOASSAY MARKET FOR NEWBORN SCREENING, BY COUNTRY, 2023–2030 (USD MILLION) 241 TABLE 243 EUROPE: IMMUNOASSAY MARKET FOR NEWBORN SCREENING, BY COUNTRY, 2023–2030 (USD MILLION) 241 TABLE 244 ASIA PACIFIC: IMMUNOASSAY MARKET FOR NEWBORN SCREENING, BY COUNTRY, 2023–2030 (USD MILLION) 242 TABLE 245 LATIN AMERICA: IMMUNOASSAY MARKET FOR NEWBORN SCREENING, BY COUNTRY, 2023–2030 (USD MILLION) 242 TABLE 246 IMMUNOASSAY MARKET FOR OTHER APPLICATIONS, BY REGION, 2023–2030 (USD MILLION) 243 TABLE 247 NORTH AMERICA: IMMUNOASSAY MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2023–2030 (USD MILLION) 244 TABLE 248 EUROPE: IMMUNOASSAY MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2023–2030 (USD MILLION) 244 TABLE 249 ASIA PACIFIC: IMMUNOASSAY MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2023–2030 (USD MILLION) 245 TABLE 250 LATIN AMERICA: IMMUNOASSAY MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2023–2030 (USD MILLION) 245 TABLE 251 IMMUNOASSAY MARKET, BY END USER, 2023–2030 (USD MILLION) 247 TABLE 252 IMMUNOASSAY END USER MARKET, BY REGION, 2023–2030 (USD MILLION) 247 TABLE 253 NORTH AMERICA: IMMUNOASSAY END USER MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 248 TABLE 254 EUROPE: IMMUNOASSAY END USER MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 248 TABLE 255 ASIA PACIFIC: IMMUNOASSAY END USER MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 249 TABLE 256 LATIN AMERICA: IMMUNOASSAY END USER MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 249 TABLE 257 IMMUNOASSAY MARKET FOR HOSPITALS & CLINICS, BY REGION, 2023–2030 (USD MILLION) 251 TABLE 258 NORTH AMERICA: IMMUNOASSAY MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2023–2030 (USD MILLION) 252 TABLE 259 EUROPE: IMMUNOASSAY MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2023–2030 (USD MILLION) 252 TABLE 260 ASIA PACIFIC: IMMUNOASSAY MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2023–2030 (USD MILLION) 253 TABLE 261 LATIN AMERICA: IMMUNOASSAY MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2023–2030 (USD MILLION) 253 TABLE 262 IMMUNOASSAY MARKET FOR CLINICAL LABORATORIES, BY REGION, 2023–2030 (USD MILLION) 255 TABLE 263 NORTH AMERICA: IMMUNOASSAY MARKET FOR CLINICAL LABORATORIES, BY COUNTRY, 2023–2030 (USD MILLION) 255 TABLE 264 EUROPE: IMMUNOASSAY MARKET FOR CLINICAL LABORATORIES, BY COUNTRY, 2023–2030 (USD MILLION) 256 TABLE 265 ASIA PACIFIC: IMMUNOASSAY MARKET FOR CLINICAL LABORATORIES, BY COUNTRY, 2023–2030 (USD MILLION) 256 TABLE 266 LATIN AMERICA: IMMUNOASSAY MARKET FOR CLINICAL LABORATORIES, BY COUNTRY, 2023–2030 (USD MILLION) 257 TABLE 267 IMMUNOASSAY MARKET FOR HOME CARE SETTINGS, BY REGION, 2023–2030 (USD MILLION) 258 TABLE 268 NORTH AMERICA: IMMUNOASSAY MARKET FOR HOME CARE SETTINGS, BY COUNTRY, 2023–2030 (USD MILLION) 258 TABLE 269 EUROPE: IMMUNOASSAY MARKET FOR HOME CARE SETTINGS, BY COUNTRY, 2023–2030 (USD MILLION) 259 TABLE 270 ASIA PACIFIC: IMMUNOASSAY MARKET FOR HOME CARE SETTINGS, BY COUNTRY, 2023–2030 (USD MILLION) 259 TABLE 271 LATIN AMERICA: IMMUNOASSAY MARKET FOR HOME CARE SETTINGS, BY COUNTRY, 2023–2030 (USD MILLION) 260 TABLE 272 IMMUNOASSAY MARKET FOR BLOOD BANKS, BY REGION, 2023–2030 (USD MILLION) 261 TABLE 273 NORTH AMERICA: IMMUNOASSAY MARKET FOR BLOOD BANKS, BY COUNTRY, 2023–2030 (USD MILLION) 261 TABLE 274 EUROPE: IMMUNOASSAY MARKET FOR BLOOD BANKS, BY COUNTRY, 2023–2030 (USD MILLION) 262 TABLE 275 ASIA PACIFIC: IMMUNOASSAY MARKET FOR BLOOD BANKS, BY COUNTRY, 2023–2030 (USD MILLION) 262 TABLE 276 LATIN AMERICA: IMMUNOASSAY MARKET FOR BLOOD BANKS, BY COUNTRY, 2023–2030 (USD MILLION) 263 TABLE 277 IMMUNOASSAY MARKET, BY REGION, 2023–2030 (USD MILLION) 265 TABLE 278 NORTH AMERICA: KEY MACROINDICATORS 266 TABLE 279 NORTH AMERICA: IMMUNOASSAY MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 268 TABLE 280 NORTH AMERICA: IMMUNOASSAY MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 268 TABLE 281 NORTH AMERICA: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE, 2023–2030 (USD MILLION) 269 TABLE 282 NORTH AMERICA: IMMUNOASSAY ANALYZERS MARKET, BY TYPE, 2023–2030 (USD MILLION) 269 TABLE 283 NORTH AMERICA: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE, 2023–2030 (USD MILLION) 270 TABLE 284 NORTH AMERICA: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 270 TABLE 285 NORTH AMERICA: IMMUNOASSAY MARKET, BY SPECIMEN, 2023–2030 (USD MILLION) 271 TABLE 286 NORTH AMERICA: IMMUNOASSAY MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 271 TABLE 287 NORTH AMERICA: IMMUNOASSAY MARKET, BY END USER, 2023–2030 (USD MILLION) 272 TABLE 288 US: NUMBER OF IN VITRO DIAGNOSTICS TESTS CONDUCTED, 2022–2030 (BILLION UNITS) 273 TABLE 289 US: IMMUNOASSAY MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 274 TABLE 290 US: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE, 2023–2030 (USD MILLION) 274 TABLE 291 US: IMMUNOASSAY ANALYZERS MARKET, BY TYPE, 2023–2030 (USD MILLION) 275 TABLE 292 US: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE, 2023–2030 (USD MILLION) 275 TABLE 293 US: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 276 TABLE 294 US: IMMUNOASSAY MARKET, BY SPECIMEN, 2023–2030 (USD MILLION) 276 TABLE 295 US: IMMUNOASSAY MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 277 TABLE 296 US: IMMUNOASSAY MARKET, BY END USER, 2023–2030 (USD MILLION) 277 TABLE 297 CANADA: ESTIMATED PREVALENCE OF DIABETES, 2024 VS. 2034 278 TABLE 298 CANADA: IMMUNOASSAY MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 279 TABLE 299 CANADA: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE, 2023–2030 (USD MILLION) 279 TABLE 300 CANADA: IMMUNOASSAY ANALYZERS MARKET, BY TYPE, 2023–2030 (USD MILLION) 280 TABLE 301 CANADA: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE, 2023–2030 (USD MILLION) 280 TABLE 302 CANADA: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 281 TABLE 303 CANADA: IMMUNOASSAY MARKET, BY SPECIMEN, 2023–2030 (USD MILLION) 281 TABLE 304 CANADA: IMMUNOASSAY MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 282 TABLE 305 CANADA: IMMUNOASSAY MARKET, BY END USER, 2023–2030 (USD MILLION) 282 TABLE 306 EUROPE: KEY MACROINDICATORS 284 TABLE 307 EUROPE: IMMUNOASSAY MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 284 TABLE 308 EUROPE: IMMUNOASSAY MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 285 TABLE 309 EUROPE: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE, 2023–2030 (USD MILLION) 285 TABLE 310 EUROPE: IMMUNOASSAY ANALYZERS MARKET, BY TYPE, 2023–2030 (USD MILLION) 286 TABLE 311 EUROPE: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE, 2023–2030 (USD MILLION) 286 TABLE 312 EUROPE: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 287 TABLE 313 EUROPE: IMMUNOASSAY MARKET, BY SPECIMEN, 2023–2030 (USD MILLION) 287 TABLE 314 EUROPE: IMMUNOASSAY MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 288 TABLE 315 EUROPE: IMMUNOASSAY MARKET, BY END USER, 2023–2030 (USD MILLION) 288 TABLE 316 GERMANY: IMMUNOASSAY MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 290 TABLE 317 GERMANY: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE, 2023–2030 (USD MILLION) 290 TABLE 318 GERMANY: IMMUNOASSAY ANALYZERS MARKET, BY TYPE, 2023–2030 (USD MILLION) 291 TABLE 319 GERMANY: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE, 2023–2030 (USD MILLION) 291 TABLE 320 GERMANY: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 292 TABLE 321 GERMANY: IMMUNOASSAY MARKET, BY SPECIMEN, 2023–2030 (USD MILLION) 292 TABLE 322 GERMANY: IMMUNOASSAY MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 293 TABLE 323 GERMANY: IMMUNOASSAY MARKET, BY END USER, 2023–2030 (USD MILLION) 293 TABLE 324 ITALY: IMMUNOASSAY MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 294 TABLE 325 ITALY: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE, 2023–2030 (USD MILLION) 295 TABLE 326 ITALY: IMMUNOASSAY ANALYZERS MARKET, BY TYPE, 2023–2030 (USD MILLION) 295 TABLE 327 ITALY: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE, 2023–2030 (USD MILLION) 296 TABLE 328 ITALY: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 296 TABLE 329 ITALY: IMMUNOASSAY MARKET, BY SPECIMEN, 2023–2030 (USD MILLION) 297 TABLE 330 ITALY: IMMUNOASSAY MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 297 TABLE 331 ITALY: IMMUNOASSAY MARKET, BY END USER, 2023–2030 (USD MILLION) 298 TABLE 332 FRANCE: IMMUNOASSAY MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 299 TABLE 333 FRANCE: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE, 2023–2030 (USD MILLION) 299 TABLE 334 FRANCE: IMMUNOASSAY ANALYZERS MARKET, BY TYPE, 2023–2030 (USD MILLION) 300 TABLE 335 FRANCE: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE, 2023–2030 (USD MILLION) 300 TABLE 336 FRANCE: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 301 TABLE 337 FRANCE: IMMUNOASSAY MARKET, BY SPECIMEN, 2023–2030 (USD MILLION) 301 TABLE 338 FRANCE: IMMUNOASSAY MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 302 TABLE 339 FRANCE: IMMUNOASSAY MARKET, BY END USER, 2023–2030 (USD MILLION) 302 TABLE 340 SPAIN: IMMUNOASSAY MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 303 TABLE 341 SPAIN: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE, 2023–2030 (USD MILLION) 304 TABLE 342 SPAIN: IMMUNOASSAY ANALYZERS MARKET, BY TYPE, 2023–2030 (USD MILLION) 304 TABLE 343 SPAIN: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE, 2023–2030 (USD MILLION) 305 TABLE 344 SPAIN: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 305 TABLE 345 SPAIN: IMMUNOASSAY MARKET, BY SPECIMEN, 2023–2030 (USD MILLION) 306 TABLE 346 SPAIN: IMMUNOASSAY MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 306 TABLE 347 SPAIN: IMMUNOASSAY MARKET, BY END USER, 2023–2030 (USD MILLION) 307 TABLE 348 UK: IMMUNOASSAY MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 309 TABLE 349 UK: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE, 2023–2030 (USD MILLION) 309 TABLE 350 UK: IMMUNOASSAY ANALYZERS MARKET, BY TYPE, 2023–2030 (USD MILLION) 310 TABLE 351 UK: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE, 2023–2030 (USD MILLION) 310 TABLE 352 UK: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 311 TABLE 353 UK: IMMUNOASSAY MARKET, BY SPECIMEN, 2023–2030 (USD MILLION) 311 TABLE 354 UK: IMMUNOASSAY MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 312 TABLE 355 UK: IMMUNOASSAY MARKET, BY END USER, 2023–2030 (USD MILLION) 312 TABLE 356 RUSSIA: IMMUNOASSAY MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 313 TABLE 357 RUSSIA: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE, 2023–2030 (USD MILLION) 314 TABLE 358 RUSSIA: IMMUNOASSAY ANALYZERS MARKET, BY TYPE, 2023–2030 (USD MILLION) 314 TABLE 359 RUSSIA: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE, 2023–2030 (USD MILLION) 315 TABLE 360 RUSSIA: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 315 TABLE 361 RUSSIA: IMMUNOASSAY MARKET, BY SPECIMEN, 2023–2030 (USD MILLION) 316 TABLE 362 RUSSIA: IMMUNOASSAY MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 316 TABLE 363 RUSSIA: IMMUNOASSAY MARKET, BY END USER, 2023–2030 (USD MILLION) 317 TABLE 364 REST OF EUROPE: IMMUNOASSAY MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 318 TABLE 365 REST OF EUROPE: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE, 2023–2030 (USD MILLION) 318 TABLE 366 REST OF EUROPE: IMMUNOASSAY ANALYZERS MARKET, BY TYPE, 2023–2030 (USD MILLION) 319 TABLE 367 REST OF EUROPE: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE, 2023–2030 (USD MILLION) 319 TABLE 368 REST OF EUROPE: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 320 TABLE 369 REST OF EUROPE: IMMUNOASSAY MARKET, BY SPECIMEN, 2023–2030 (USD MILLION) 320 TABLE 370 REST OF EUROPE: IMMUNOASSAY MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 321 TABLE 371 REST OF EUROPE: IMMUNOASSAY MARKET, BY END USER, 2023–2030 (USD MILLION) 321 TABLE 372 ASIA PACIFIC: KEY MACROINDICATORS 322 TABLE 373 ASIA PACIFIC: IMMUNOASSAY MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 324 TABLE 374 ASIA PACIFIC: IMMUNOASSAY MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 324 TABLE 375 ASIA PACIFIC: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE, 2023–2030 (USD MILLION) 325 TABLE 376 ASIA PACIFIC: IMMUNOASSAY ANALYZERS MARKET, BY TYPE, 2023–2030 (USD MILLION) 325 TABLE 377 ASIA PACIFIC: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE, 2023–2030 (USD MILLION) 326 TABLE 378 ASIA PACIFIC: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 326 TABLE 379 ASIA PACIFIC: IMMUNOASSAY MARKET, BY SPECIMEN, 2023–2030 (USD MILLION) 327 TABLE 380 ASIA PACIFIC: IMMUNOASSAY MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 327 TABLE 381 ASIA PACIFIC: IMMUNOASSAY MARKET, BY END USER, 2023–2030 (USD MILLION) 328 TABLE 382 JAPAN: IMMUNOASSAY MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 329 TABLE 383 JAPAN: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE, 2023–2030 (USD MILLION) 329 TABLE 384 JAPAN: IMMUNOASSAY ANALYZERS MARKET, BY TYPE, 2023–2030 (USD MILLION) 330 TABLE 385 JAPAN: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE, 2023–2030 (USD MILLION) 330 TABLE 386 JAPAN: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 331 TABLE 387 JAPAN: IMMUNOASSAY MARKET, BY SPECIMEN, 2023–2030 (USD MILLION) 331 TABLE 388 JAPAN: IMMUNOASSAY MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 332 TABLE 389 JAPAN: IMMUNOASSAY MARKET, BY END USER, 2023–2030 (USD MILLION) 332 TABLE 390 CHINA: IMMUNOASSAY MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 333 TABLE 391 CHINA: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE, 2023–2030 (USD MILLION) 334 TABLE 392 CHINA: IMMUNOASSAY ANALYZERS MARKET, BY TYPE, 2023–2030 (USD MILLION) 334 TABLE 393 CHINA: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE, 2023–2030 (USD MILLION) 335 TABLE 394 CHINA: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 335 TABLE 395 CHINA: IMMUNOASSAY MARKET, BY SPECIMEN, 2023–2030 (USD MILLION) 336 TABLE 396 CHINA: IMMUNOASSAY MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 336 TABLE 397 CHINA: IMMUNOASSAY MARKET, BY END USER, 2023–2030 (USD MILLION) 337 TABLE 398 INDIA: IMMUNOASSAY MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 338 TABLE 399 INDIA: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE, 2023–2030 (USD MILLION) 339 TABLE 400 INDIA: IMMUNOASSAY ANALYZERS MARKET, BY TYPE, 2023–2030 (USD MILLION) 339 TABLE 401 INDIA: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE, 2023–2030 (USD MILLION) 340 TABLE 402 INDIA: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 340 TABLE 403 INDIA: IMMUNOASSAY MARKET, BY SPECIMEN, 2023–2030 (USD MILLION) 341 TABLE 404 INDIA: IMMUNOASSAY MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 341 TABLE 405 INDIA: IMMUNOASSAY MARKET, BY END USER, 2023–2030 (USD MILLION) 342 TABLE 406 AUSTRALIA: IMMUNOASSAY MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 343 TABLE 407 AUSTRALIA: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE, 2023–2030 (USD MILLION) 343 TABLE 408 AUSTRALIA: IMMUNOASSAY ANALYZERS MARKET, BY TYPE, 2023–2030 (USD MILLION) 344 TABLE 409 AUSTRALIA: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE, 2023–2030 (USD MILLION) 344 TABLE 410 AUSTRALIA: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 345 TABLE 411 AUSTRALIA: IMMUNOASSAY MARKET, BY SPECIMEN, 2023–2030 (USD MILLION) 345 TABLE 412 AUSTRALIA: IMMUNOASSAY MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 346 TABLE 413 AUSTRALIA: IMMUNOASSAY MARKET, BY END USER, 2023–2030 (USD MILLION) 346 TABLE 414 SOUTH KOREA: IMMUNOASSAY MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 347 TABLE 415 SOUTH KOREA: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE, 2023–2030 (USD MILLION) 348 TABLE 416 SOUTH KOREA: IMMUNOASSAY ANALYZERS MARKET, BY TYPE, 2023–2030 (USD MILLION) 348 TABLE 417 SOUTH KOREA: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE, 2023–2030 (USD MILLION) 349 TABLE 418 SOUTH KOREA: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 349 TABLE 419 SOUTH KOREA: IMMUNOASSAY MARKET, BY SPECIMEN, 2023–2030 (USD MILLION) 350 TABLE 420 SOUTH KOREA: IMMUNOASSAY MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 350 TABLE 421 SOUTH KOREA: IMMUNOASSAY MARKET, BY END USER, 2023–2030 (USD MILLION) 351 TABLE 422 INDONESIA: IMMUNOASSAY MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 352 TABLE 423 INDONESIA: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE, 2023–2030 (USD MILLION) 352 TABLE 424 INDONESIA: IMMUNOASSAY ANALYZERS MARKET, BY TYPE, 2023–2030 (USD MILLION) 353 TABLE 425 INDONESIA: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE, 2023–2030 (USD MILLION) 353 TABLE 426 INDONESIA: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 354 TABLE 427 INDONESIA: IMMUNOASSAY MARKET, BY SPECIMEN, 2023–2030 (USD MILLION) 354 TABLE 428 INDONESIA: IMMUNOASSAY MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 355 TABLE 429 INDONESIA: IMMUNOASSAY MARKET, BY END USER, 2023–2030 (USD MILLION) 355 TABLE 430 REST OF ASIA PACIFIC: IMMUNOASSAY MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 356 TABLE 431 REST OF ASIA PACIFIC: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE, 2023–2030 (USD MILLION) 357 TABLE 432 REST OF ASIA PACIFIC: IMMUNOASSAY ANALYZERS MARKET, BY TYPE, 2023–2030 (USD MILLION) 357 TABLE 433 REST OF ASIA PACIFIC: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE, 2023–2030 (USD MILLION) 358 TABLE 434 REST OF ASIA PACIFIC: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 358 TABLE 435 REST OF ASIA PACIFIC: IMMUNOASSAY MARKET, BY SPECIMEN, 2023–2030 (USD MILLION) 359 TABLE 436 REST OF ASIA PACIFIC: IMMUNOASSAY MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 359 TABLE 437 REST OF ASIA PACIFIC: IMMUNOASSAY MARKET, BY END USER, 2023–2030 (USD MILLION) 360 TABLE 438 LATIN AMERICA: KEY MACROINDICATORS 361 TABLE 439 LATIN AMERICA: IMMUNOASSAY MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 361 TABLE 440 LATIN AMERICA: IMMUNOASSAY MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 361 TABLE 441 LATIN AMERICA: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE, 2023–2030 (USD MILLION) 362 TABLE 442 LATIN AMERICA: IMMUNOASSAY ANALYZERS MARKET, BY TYPE, 2023–2030 (USD MILLION) 362 TABLE 443 LATIN AMERICA: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE, 2023–2030 (USD MILLION) 363 TABLE 444 LATIN AMERICA: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 363 TABLE 445 LATIN AMERICA: IMMUNOASSAY MARKET, BY SPECIMEN, 2023–2030 (USD MILLION) 364 TABLE 446 LATIN AMERICA: IMMUNOASSAY MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 364 TABLE 447 LATIN AMERICA: IMMUNOASSAY MARKET, BY END USER, 2023–2030 (USD MILLION) 365 TABLE 448 BRAZIL: IMMUNOASSAY MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 366 TABLE 449 BRAZIL: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE, 2023–2030 (USD MILLION) 366 TABLE 450 BRAZIL: IMMUNOASSAY ANALYZERS MARKET, BY TYPE, 2023–2030 (USD MILLION) 367 TABLE 451 BRAZIL: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE, 2023–2030 (USD MILLION) 367 TABLE 452 BRAZIL: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 368 TABLE 453 BRAZIL: IMMUNOASSAY MARKET, BY SPECIMEN, 2023–2030 (USD MILLION) 368 TABLE 454 BRAZIL: IMMUNOASSAY MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 369 TABLE 455 BRAZIL: IMMUNOASSAY MARKET, BY END USER, 2023–2030 (USD MILLION) 369 TABLE 456 MEXICO: IMMUNOASSAY MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 370 TABLE 457 MEXICO: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE, 2023–2030 (USD MILLION) 371 TABLE 458 MEXICO: IMMUNOASSAY ANALYZERS MARKET, BY TYPE, 2023–2030 (USD MILLION) 371 TABLE 459 MEXICO: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE, 2023–2030 (USD MILLION) 372 TABLE 460 MEXICO: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 372 TABLE 461 MEXICO: IMMUNOASSAY MARKET, BY SPECIMEN, 2023–2030 (USD MILLION) 373 TABLE 462 MEXICO: IMMUNOASSAY MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 373 TABLE 463 MEXICO: IMMUNOASSAY MARKET, BY END USER, 2023–2030 (USD MILLION) 374 TABLE 464 REST OF LATIN AMERICA: IMMUNOASSAY MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 375 TABLE 465 REST OF LATIN AMERICA: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE, 2023–2030 (USD MILLION) 375 TABLE 466 REST OF LATIN AMERICA: IMMUNOASSAY ANALYZERS MARKET, BY TYPE, 2023–2030 (USD MILLION) 376 TABLE 467 REST OF LATIN AMERICA: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE, 2023–2030 (USD MILLION) 376 TABLE 468 REST OF LATIN AMERICA: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 377 TABLE 469 REST OF LATIN AMERICA: IMMUNOASSAY MARKET, BY SPECIMEN, 2023–2030 (USD MILLION) 377 TABLE 470 REST OF LATIN AMERICA: IMMUNOASSAY MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 378 TABLE 471 REST OF LATIN AMERICA: IMMUNOASSAY MARKET, BY END USER, 2023–2030 (USD MILLION) 378 TABLE 472 MIDDLE EAST & AFRICA: IMMUNOASSAY MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 380 TABLE 473 MIDDLE EAST & AFRICA: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE, 2023–2030 (USD MILLION) 380 TABLE 474 MIDDLE EAST & AFRICA: IMMUNOASSAY ANALYZERS MARKET, BY TYPE, 2023–2030 (USD MILLION) 381 TABLE 475 MIDDLE EAST & AFRICA: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE, 2023–2030 (USD MILLION) 381 TABLE 476 MIDDLE EAST & AFRICA: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 382 TABLE 477 MIDDLE EAST & AFRICA: IMMUNOASSAY MARKET, BY SPECIMEN, 2023–2030 (USD MILLION) 382 TABLE 478 MIDDLE EAST & AFRICA: IMMUNOASSAY MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 383 TABLE 479 MIDDLE EAST & AFRICA: IMMUNOASSAY MARKET, BY END USER, 2023–2030 (USD MILLION) 383 TABLE 480 OVERVIEW OF KEY STRATEGIES DEPLOYED BY MAJOR PLAYERS IN IMMUNOASSAY MARKET 384 TABLE 481 IMMUNOASSAY MARKET: DEGREE OF COMPETITION 387 TABLE 482 IMMUNOASSAY MARKET: REGION FOOTPRINT 391 TABLE 483 IMMUNOASSAY MARKET: PRODUCT FOOTPRINT 392 TABLE 484 IMMUNOASSAY MARKET: SPECIMEN FOOTPRINT 393 TABLE 485 IMMUNOASSAY MARKET: LIST OF KEY STARTUPS/SME PLAYERS 396 TABLE 486 IMMUNOASSAY MARKET: COMPETITIVE BENCHMARKING OF STARTUPS/ SME PLAYERS, BY REGION 397 TABLE 487 IMMUNOASSAY MARKET: PRODUCT LAUNCHES/APPROVALS/ENHANCEMENTS, JANUARY 2022–JULY 2025 399 TABLE 488 IMMUNOASSAY MARKET: DEALS, JANUARY 2022–JULY 2025 400 TABLE 489 ABBOTT: COMPANY OVERVIEW 402 TABLE 490 ABBOTT: PRODUCTS OFFERED 403 TABLE 491 ABBOTT: PRODUCT APPROVALS, JANUARY 2022–JUNE 2025 405 TABLE 492 ABBOTT: DEALS, JANUARY 2022–JUNE 2025 406 TABLE 493 ABBOTT: EXPANSIONS, JANUARY 2022–JUNE 2025 407 TABLE 494 F. HOFFMANN-LA ROCHE LTD.: COMPANY OVERVIEW 408 TABLE 495 F. HOFFMANN-LA ROCHE LTD.: PRODUCTS OFFERED 409 TABLE 496 F. HOFFMANN-LA ROCHE LTD.: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022–JUNE 2025 412 TABLE 497 F. HOFFMANN-LA ROCHE LTD.: DEALS, JANUARY 2022–JUNE 2025 412 TABLE 498 F. HOFFMANN-LA ROCHE LTD.: EXPANSIONS, JANUARY 2022–JUNE 2025 413 TABLE 499 SIEMENS HEALTHINEERS AG: COMPANY OVERVIEW 415 TABLE 500 SIEMENS HEALTHINEERS AG: PRODUCTS OFFERED 416 TABLE 501 SIEMENS HEALTHINEERS AG: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022–JUNE 2025 418 TABLE 502 SIEMENS HEALTHINEERS AG: DEALS, JANUARY 2022–JUNE 2025 418 TABLE 503 SIEMENS HEALTHINEERS AG: EXPANSIONS, JANUARY 2022–JUNE 2025 419 TABLE 504 DANAHER: COMPANY OVERVIEW 421 TABLE 505 DANAHER: PRODUCTS OFFERED 422 TABLE 506 DANAHER: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022–JUNE 2025 423 TABLE 507 DANAHER: DEALS, JANUARY 2022–JUNE 2025 424 TABLE 508 DANAHER: EXPANSIONS, JANUARY 2022–JUNE 2025 425 TABLE 509 THERMO FISHER SCIENTIFIC INC.: COMPANY OVERVIEW 427 TABLE 510 THERMO FISHER SCIENTIFIC INC.: PRODUCTS OFFERED 428 TABLE 511 THERMO FISHER SCIENTIFIC INC.: PRODUCT APPROVALS, JANUARY 2022–JUNE 2025 429 TABLE 512 THERMO FISHER SCIENTIFIC INC.: DEALS, JANUARY 2022–JUNE 2025 430 TABLE 513 REVVITY: COMPANY OVERVIEW 432 TABLE 514 REVVITY: PRODUCTS OFFERED 433 TABLE 515 REVVITY: PRODUCT APPROVALS, JANUARY 2022–JUNE 2025 434 TABLE 516 REVVITY: OTHER DEVELOPMENTS, JANUARY 2022–JUNE 2025 435 TABLE 517 BECTON, DICKINSON AND COMPANY (BD): COMPANY OVERVIEW 436 TABLE 518 BECTON, DICKINSON AND COMPANY (BD): PRODUCTS OFFERED 437 TABLE 519 BECTON, DICKINSON AND COMPANY (BD): EXPANSIONS, JANUARY 2022–JUNE 2025 438 TABLE 520 DIASORIN S.P.A.: COMPANY OVERVIEW 439 TABLE 521 DIASORIN S.P.A.: PRODUCTS OFFERED 440 TABLE 522 DIASORIN S.P.A.: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022–JUNE 2025 442 TABLE 523 DIASORIN S.P.A.: DEALS, JANUARY 2022–JUNE 2025 443 TABLE 524 BIO-RAD LABORATORIES, INC.: COMPANY OVERVIEW 444 TABLE 525 BIO-RAD LABORATORIES, INC.: PRODUCTS OFFERED 445 TABLE 526 BIO-RAD LABORATORIES, INC.: PRODUCT LAUNCHES, JANUARY 2022–JUNE 2025 447 TABLE 527 BIO-RAD LABORATORIES, INC.: DEALS, JANUARY 2022–JUNE 2025 448 TABLE 528 QUIDELORTHO CORPORATION: COMPANY OVERVIEW 449 TABLE 529 QUIDELORTHO CORPORATION: PRODUCTS OFFERED 450 TABLE 530 QUIDELORTHO CORPORATION: PRODUCT APPROVALS, JANUARY 2022–JUNE 2025 453 TABLE 531 QUIDELORTHO CORPORATION: DEALS, JANUARY 2022–JUNE 2025 453 TABLE 532 QUIDELORTHO CORPORATION: EXPANSIONS, JANUARY 2022–JUNE 2025 454 TABLE 533 BIOMÉRIEUX: COMPANY OVERVIEW 455 TABLE 534 BIOMÉRIEUX: PRODUCTS OFFERED 456 TABLE 535 BIOMÉRIEUX: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022–JUNE 2025 457 TABLE 536 BIOMÉRIEUX: DEALS, JANUARY 2022–JUNE 2025 458 TABLE 537 QIAGEN: COMPANY OVERVIEW 459 TABLE 538 QIAGEN: PRODUCTS OFFERED 460 TABLE 539 QIAGEN: DEALS, JANUARY 2022–JUNE 2025 461 TABLE 540 SYSMEX CORPORATION: COMPANY OVERVIEW 462 TABLE 541 SYSMEX CORPORATION: PRODUCTS OFFERED 464 TABLE 542 SYSMEX CORPORATION: DEALS, JANUARY 2022–JUNE 2025 464 TABLE 543 SYSMEX CORPORATION: EXPANSIONS, JANUARY 2022–JUNE 2025 465 TABLE 544 AGILENT TECHNOLOGIES, INC.: COMPANY OVERVIEW 467 TABLE 545 AGILENT TECHNOLOGIES, INC.: PRODUCTS OFFERED 468 TABLE 546 AGILENT TECHNOLOGIES, INC.: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022–JUNE 2025 469 TABLE 547 AGILENT TECHNOLOGIES, INC.: DEALS, JANUARY 2022–JUNE 2025 469 TABLE 548 AGILENT TECHNOLOGIES, INC.: OTHER DEVELOPMENTS, JANUARY 2022–JUNE 2025 470 TABLE 549 SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.: COMPANY OVERVIEW 471 TABLE 550 SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.: PRODUCTS OFFERED 472 TABLE 551 MERCK KGAA: COMPANY OVERVIEW 473 TABLE 552 MERIDIAN BIOSCIENCE: COMPANY OVERVIEW 474 TABLE 553 BIO-TECHNE: COMPANY OVERVIEW 475 TABLE 554 CELLABS: COMPANY OVERVIEW 476 TABLE 555 ABNOVA CORPORATION: COMPANY OVERVIEW 477 TABLE 556 J. MITRA & CO. PVT. LTD.: COMPANY OVERVIEW 477 TABLE 557 TOSOH CORPORATION (TOSOH BIOSCIENCES): COMPANY OVERVIEW 478 TABLE 558 CELL SCIENCES: COMPANY OVERVIEW 478 TABLE 559 ENZO BIOCHEM INC.: COMPANY OVERVIEW 479 TABLE 560 CREATIVE DIAGNOSTICS: COMPANY OVERVIEW 480 TABLE 561 BOSTER BIOLOGICAL TECHNOLOGY: COMPANY OVERVIEW 480 TABLE 562 ELABSCIENCE BIONOVATON INC.: COMPANY OVERVIEW 481 TABLE 563 WAK-CHEMIE MEDICAL GMBH: COMPANY OVERVIEW 481 TABLE 564 SERA CARE: COMPANY OVERVIEW 482 TABLE 565 EPITOPE DIAGNOSTICS, INC.: COMPANY OVERVIEW 482 TABLE 566 KAMIYA BIOMEDICAL COMPANY: COMPANY OVERVIEW 483 TABLE 567 GYROS PROTEIN TECHNOLOGIES AB: COMPANY OVERVIEW 483 TABLE 568 TRIVITRON HEALTHCARE: COMPANY OVERVIEW 484 TABLE 569 INBIOS INTERNATIONAL, INC.: COMPANY OVERVIEW 484 TABLE 570 MACCURA BIOTECHNOLOGY CO., LTD.: COMPANY OVERVIEW 485 FIGURE 1 IMMUNOASSAY MARKET SEGMENTATION & REGIONAL SCOPE 40 FIGURE 2 IMMUNOASSAY MARKET: YEARS CONSIDERED 42 FIGURE 3 IMMUNOASSAY MARKET: RESEARCH DESIGN 44 FIGURE 4 IMMUNOASSAY MARKET: KEY DATA FROM SECONDARY SOURCES 46 FIGURE 5 IMMUNOASSAY MARKET: KEY PRIMARY SOURCES 47 FIGURE 6 IMMUNOASSAY MARKET: KEY INSIGHTS FROM INDUSTRY EXPERTS 49 FIGURE 7 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY- AND DEMAND-SIDE PARTICIPANTS 50 FIGURE 8 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION 50 FIGURE 9 IMMUNOASSAY MARKET: COMPANY REVENUE ESTIMATION (REVENUE SHARE ANALYSIS) 51 FIGURE 10 IMMUNOASSAY MARKET: CAGR PROJECTIONS (SUPPLY-SIDE ANALYSIS) 52 FIGURE 11 IMMUNOASSAY MARKET: TOP-DOWN APPROACH 53 FIGURE 12 IMMUNOASSAY MARKET: DATA TRIANGULATION METHODOLOGY 54 FIGURE 13 IMMUNOASSAY MARKET, BY PRODUCT, 2025 VS. 2030 (USD BILLION) 57 FIGURE 14 IMMUNOASSAY MARKET, BY TECHNOLOGY, 2025 VS. 2030 (USD BILLION) 58 FIGURE 15 IMMUNOASSAY MARKET, BY SPECIMEN, 2025 VS. 2030 (USD BILLION) 59 FIGURE 16 IMMUNOASSAY MARKET, BY APPLICATION, 2025 VS. 2030 (USD BILLION) 60 FIGURE 17 IMMUNOASSAY MARKET, BY END USER, 2025 VS. 2030 (USD BILLION) 61 FIGURE 18 REGIONAL SNAPSHOT OF IMMUNOASSAY MARKET 62 FIGURE 19 FAVORABLE REGULATORY SCENARIO AND HIGH PREVALENCE OF INFECTIOUS DISEASES TO DRIVE MARKET 63 FIGURE 20 US AND REAGENTS & KITS COMMANDED LARGEST SHARE OF NORTH AMERICAN IMMUNOASSAY MARKET IN 2024 64 FIGURE 21 CHINA TO WITNESS HIGHEST GROWTH RATE DURING FORECAST PERIOD 65 FIGURE 22 ASIA PACIFIC TO WITNESS HIGHEST CAGR DURING STUDY PERIOD 66 FIGURE 23 IMMUNOASSAY MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 67 FIGURE 24 RATE OF INCREASE IN INCIDENCE OF DIABETES GLOBALLY (IN MILLION) 68 FIGURE 25 US: REGULATORY PROCESS FOR IN-VIRTO DIAGNOSTIC DEVICES 81 FIGURE 26 CANADA: REGULATORY PROCESS FOR IN-VIRTO DIAGNOSTIC DEVICES 82 FIGURE 27 JAPAN: REGULATORY PROCESS FOR IN-VIRTO DIAGNOSTIC DEVICES 84 FIGURE 28 INDIA: REGULATORY PROCESS FOR IN-VIRTO DIAGNOSTIC DEVICES 86 FIGURE 29 MEXICO: REGULATORY PROCESS FOR IN-VIRTO DIAGNOSTIC DEVICES 88 FIGURE 30 BRAZIL: REGULATORY PROCESS FOR IN-VIRTO DIAGNOSTIC DEVICES 90 FIGURE 31 TOP 10 PATENT OWNERS/APPLICANTS IN IMMUNOASSAY MARKET, JANUARY 2015–DECEMBER 2024 96 FIGURE 32 IMMUNOASSAY MARKET: VALUE CHAIN ANALYSIS 97 FIGURE 33 IMMUNOASSAY MARKET: SUPPLY CHAIN ANALYSIS 98 FIGURE 34 IMMUNOASSAY MARKET: ECOSYSTEM ANALYSIS 99 FIGURE 35 IMMUNOASSAY MARKET: PORTER’S FIVE FORCES ANALYSIS 101 FIGURE 36 INFLUENCE OF KEY STAKEHOLDERS ON BUYING PROCESS, BY END USER 103 FIGURE 37 KEY BUYING CRITERIA FOR TOP END USERS 103 FIGURE 38 IMMUNOASSAY MARKET: TRENDS/DISTRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 108 FIGURE 39 IMMUNOASSAY MARKET: FUNDING AND NUMBER OF DEALS, 2018−2025 (USD MILLION) 110 FIGURE 40 MARKET POTENTIAL OF AI/GEN AI IN ENHANCING IMMUNOASSAY DIAGNOSIS AND TREATMENT PLANNING 112 FIGURE 41 NORTH AMERICA: IMMUNOASSAY MARKET SNAPSHOT 267 FIGURE 42 ASIA PACIFIC: IMMUNOASSAY MARKET SNAPSHOT 323 FIGURE 43 REVENUE ANALYSIS OF KEY PLAYERS IN IMMUNOASSAY MARKET (2020–2024) 386 FIGURE 44 MARKET SHARE ANALYSIS OF KEY PLAYERS IN IMMUNOASSAY MARKET (2024) 387 FIGURE 45 IMMUNOASSAY MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2024 389 FIGURE 46 IMMUNOASSAY MARKET: COMPANY FOOTPRINT 390 FIGURE 47 IMMUNOASSAY MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2024 395 FIGURE 48 EV/EBITDA OF KEY VENDORS, 2025 398 FIGURE 49 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS, 2025 398 FIGURE 50 IMMUNOASSAY MARKET: BRAND/PRODUCT COMPARATIVE ANALYSIS 399 FIGURE 51 ABBOTT: COMPANY SNAPSHOT 403 FIGURE 52 F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT 409 FIGURE 53 SIEMENS HEALTHINEERS AG: COMPANY SNAPSHOT 416 FIGURE 54 DANAHER: COMPANY SNAPSHOT 422 FIGURE 55 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT 428 FIGURE 56 REVVITY: COMPANY SNAPSHOT 433 FIGURE 57 BECTON, DICKINSON AND COMPANY (BD): COMPANY SNAPSHOT 437 FIGURE 58 DIASORIN S.P.A.: COMPANY SNAPSHOT 440 FIGURE 59 BIO-RAD LABORATORIES, INC.: COMPANY SNAPSHOT 445 FIGURE 60 QUIDELORTHO CORPORATION: COMPANY SNAPSHOT 450 FIGURE 61 BIOMÉRIEUX: COMPANY SNAPSHOT 456 FIGURE 62 QIAGEN: COMPANY SNAPSHOT 460 FIGURE 63 SYSMEX CORPORATION: COMPANY SNAPSHOT 463 FIGURE 64 AGILENT TECHNOLOGIES, INC.: COMPANY SNAPSHOT 468 FIGURE 65 SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.: COMPANY SNAPSHOT 471